• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by ResMed Inc.

    11/21/24 5:20:32 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    8-K
    RESMED INC US false 0000943819 0000943819 2024-11-20 2024-11-20

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    November 20, 2024

    Date of Report (Date of earliest event reported)

     

     

    ResMed Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-15317   98-0152841

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    9001 Spectrum Center Boulevard

    San Diego, California 92123

    (Address of Principal Executive Offices) (Zip Code)

    (858) 836-5000

    (Registrant’s telephone number, including area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.004 par value   RMD   NYSE

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) ☐

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

     

     

     


    Item 5.07.

    Submission of Matters to a Vote of Security Holders.

    On November 20, 2024, at our annual meeting of stockholders, our stockholders (1) elected the eleven nominees listed below to serve on our board of directors; (2) ratified the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2025; and (3) approved, on an advisory basis, the compensation of our named executive officers (“say-on-pay”).

     

         For      Against      Abstain      Broker
    Non-Votes
     

    Item of business 1: Elect the following eleven directors, each to serve until our 2025 annual meeting and until their successors are elected and qualified:

               

    Carol Burt

         105,566,293        4,609,884        81,094        4,969,328  

    Christopher DelOrefice

         109,836,913        337,767        82,591        4,969,328  

    Jan De Witte

         109,745,710        430,055        81,506        4,969,328  

    Karen Drexler

         101,135,602        9,042,745        78,924        4,969,328  

    Michael Farrell

         105,058,243        4,724,177        474,851        4,969,328  

    Peter Farrell

         107,590,325        2,605,639        61,307        4,969,328  

    Harjit Gill

         109,303,018        871,110        83,143        4,969,328  

    John Hernandez

         109,431,549        743,605        82,117        4,969,328  

    Richard Sulpizio

         88,007,747        22,003,356        246,168        4,969,328  

    Desney Tan

         109,241,632        934,672        80,967        4,969,328  

    Ronald Taylor

         95,465,730        14,705,330        86,211        4,969,328  
         For      Against      Abstain      Broker
    Non-Votes
     

    Item of business 2: Ratify our selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2025.

         105,082,628        10,096,722        47,249     
         For      Against      Abstain      Broker
    Non-Votes
     

    Item of business 3: Approve, on an advisory basis, the compensation of our named executive officers, as disclosed in our proxy statement (“say-on-pay”).

         92,885,004        17,284,647        87,620        4,969,328  


    SIGNATURES

    We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

     

      RESMED INC.
    Date: November 21, 2024   By:  

    /s/ Michael Rider

        Michael Rider
        Chief Legal Officer, Global General Counsel and Secretary
    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    More analyst ratings

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2025. "Our second quarter results demonstrate the strength and resilience of our global business a

    1/29/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

    SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:https://investor.resmed.com•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST / 4:30 p.m. EST•International:London, Thursday, January 29, 2026, 9:30 p.m. GMT  Sydney, Friday, January 30, 2026, 8:30 a.m. AEDT Please note, Resmed

    1/8/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

    SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days. About ResmedResmed (NYSE:RMD,

    12/18/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00

    12/16/25 8:57:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by CLSA

    CLSA upgraded ResMed from Hold to Outperform

    9/2/25 11:05:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,366,436 worth of ResMed Common Stock (4,991 units at $273.78) (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/10/26 1:33:22 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Director Farrell Peter C sold $502,620 worth of ResMed Common Stock (2,000 units at $251.31), decreasing direct ownership by 3% to 64,773 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/6/26 11:07:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Global General Counsel Rider Michael J sold $13,000 worth of ResMed Common Stock (50 units at $260.00), decreasing direct ownership by 0.51% to 9,691 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/6/26 11:05:33 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    SEC Form 10-Q filed by ResMed Inc.

    10-Q - RESMED INC (0000943819) (Filer)

    1/29/26 7:37:18 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - RESMED INC (0000943819) (Filer)

    1/29/26 4:05:45 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by ResMed Inc.

    S-8 - RESMED INC (0000943819) (Filer)

    11/21/25 1:17:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2025. "Our second quarter results demonstrate the strength and resilience of our global business a

    1/29/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

    SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:https://investor.resmed.com•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST / 4:30 p.m. EST•International:London, Thursday, January 29, 2026, 9:30 p.m. GMT  Sydney, Friday, January 30, 2026, 8:30 a.m. AEDT Please note, Resmed

    1/8/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

    Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended September 30, 2025. "Our fiscal year 2026 is off to a strong start, with first-quarter performance r

    10/30/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care